Melanoma & Skin Cancer Articles

FDA Approves 4-Week Nivolumab Dosing Schedule
The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.
Obesity Linked to Improved Outcomes in Men With Metastatic Melanoma
Obese men treated with targeted or immune therapies for metastatic melanoma had a 47% reduced risk of death compared with men who had a normal BMI. 
Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma
The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs.
The PD-1 inhibitor pembrolizumab (Keytruda) continues to be a promising frontline immunotherapy option for patients with advanced melanoma.
Analysis Explores Continuing Anti-PD-1 Therapy Past Progression in Melanoma
Investigators with the FDA’s Center for Drug Evaluation and Research and Oncology Center of Excellence conducted a pooled analysis of all trial reports and data marketing applications for the use of anti–PD-1 antibodies alone or in combination to treat patients with unresectable or metastatic melanoma. 
Focus Moves to Earlier Settings in Melanoma
Novel systemic therapies in the neoadjuvant and adjuvant settings have shown promising outcomes for locally advanced melanoma and may reduce the proportion of patients who need complete lymphadenectomy.
With the advent of the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) in melanoma physicians are no longer using BRAF inhibitors alone, but rather in combination with MEK inhibitors due to the improved efficacy.
Binimetinib/Encorafenib Positive OS Data Released as FDA Weighs Melanoma Approval
Treatment with encorafenib and binimetinib improved survival versus single-agent vemurafenib (Zelboraf) in patients with BRAF-mutant advanced, unresectable or metastatic melanoma.
Complete Lymph Node Dissection Not Superior to Surveillance in Melanoma
Daniel Coit, MD, discusses clinical findings with complete lymph node dissection and the evolution of surgery in the melanoma landscape. 
Novel Combinations Continue to Advance Melanoma Field
Mario Sznol, MD, discusses overall advances in the field of melanoma, as well as novel treatments with the potential to change the treatment paradigm.
Publication Bottom Border
Border Publication